This study is looking at a condition called palmoplantar pustulosis, which is a skin disease that causes painful blisters filled with fluid to appear on the palms of the hands and soles of the feet. People with this condition often experience pain and discomfort that can affect their daily activities and quality of life. The treatment being tested in this study is called bimekizumab, which is given as an injection under the skin. Some people in the study will receive bimekizumab while others will receive placebo. The purpose of the study is to evaluate the efficacy of bimekizumab compared with placebo in participants with palmoplantar pustulosis at Week 16.
During the study, participants will receive their assigned treatment through injections that are given using pre-filled syringes or pre-filled pens. The study will measure how well the treatment works by looking at changes in the skin condition, including the number and severity of pustules on the hands and feet. Doctors will use specific scoring systems to track improvements in the skin. The study will also look at how the treatment affects pain levels and quality of life by asking participants to complete questionnaires about their symptoms and how the condition impacts their daily activities.
The study has two parts: a main treatment period and an open-label extension period where all participants may receive the active treatment. Throughout the study, doctors will carefully monitor participants for any side effects or unwanted reactions to the treatment. They will track all health problems that occur during the study, including serious health issues and any problems that might cause participants to stop taking the study treatment. Regular check-ups and assessments will be conducted to ensure participant safety and to measure how well the treatment is working over time.
Czechia 
Denmark 
France 
Germany 
Hungary 
Italy 
Poland 
Spain